RT Journal Article SR Electronic T1 Nanovesicles derived from iron oxide nanoparticles–incorporated mesenchymal stem cells for cardiac repair JF Science Advances JO Sci Adv FD American Association for the Advancement of Science SP eaaz0952 DO 10.1126/sciadv.aaz0952 VO 6 IS 18 A1 Lee, Ju-Ro A1 Park, Bong-Woo A1 Kim, Jonghoon A1 Choo, Yeon Woong A1 Kim, Han Young A1 Yoon, Jeong-Kee A1 Kim, Hyeok A1 Hwang, Ji-Won A1 Kang, Mikyung A1 Kwon, Sung Pil A1 Song, Seuk Young A1 Ko, In Ok A1 Park, Ji-Ae A1 Ban, Kiwon A1 Hyeon, Taeghwan A1 Park, Hun-Jun A1 Kim, Byung-Soo YR 2020 UL http://advances.sciencemag.org/content/6/18/eaaz0952.abstract AB Because of poor engraftment and safety concerns regarding mesenchymal stem cell (MSC) therapy, MSC-derived exosomes have emerged as an alternative cell-free therapy for myocardial infarction (MI). However, the diffusion of exosomes out of the infarcted heart following injection and the low productivity limit the potential of clinical applications. Here, we developed exosome-mimetic extracellular nanovesicles (NVs) derived from iron oxide nanoparticles (IONPs)–incorporated MSCs (IONP-MSCs). The retention of injected IONP-MSC–derived NVs (IONP-NVs) within the infarcted heart was markedly augmented by magnetic guidance. Furthermore, IONPs significantly increased the levels of therapeutic molecules in IONP-MSCs and IONP-NVs, which can reduce the concern of low exosome productivity. The injection of IONP-NVs into the infarcted heart and magnetic guidance induced an early shift from the inflammation phase to the reparative phase, reduced apoptosis and fibrosis, and enhanced angiogenesis and cardiac function recovery. This approach can enhance the therapeutic potency of an MSC-derived NV therapy.